Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B D Curti

Showing results (11-20 of 26) with videos related to

Pageof 3
Sort By:
Cancer Investigation|July 29, 1998
A phase II study of carboplatin, cisplatin, interferon-alpha, and tamoxifen for patients with metastatic melanomaB L Gause, W H Sharfman, J E Janik, et al.
Blood|April 1, 1997
Adoptive transfer of anti-CD3-activated CD4+ T cells plus cyclophosphamide and liposome-encapsulated interleukin-2 cure murine MC-38 and 3LL tumors and establish tumor-specific immunityM L Saxton, D L Longo, H E Wetzel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1993
Treatment of cancer patients with ex vivo anti-CD3-activated killer cells and interleukin-2B D Curti, D L Longo, A C Ochoa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 1995
Alterations in T cell receptor and signal transduction molecules in melanoma patientsA H Zea, B D Curti, D L Longo, et al.
The New England Journal of Medicine|March 18, 1993
The effects of treatment with interleukin-1 alpha on platelet recovery after high-dose carboplatinJ W Smith, D L Longo, W G Alvord, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1992
The toxic and hematologic effects of interleukin-1 alpha administered in a phase I trial to patients with advanced malignanciesJ W Smith, W J Urba, B D Curti, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|March 1, 1996
Endocrine effects of IL-1 alpha and beta administered in a phase I trial to patients with advanced cancerB D Curti, W J Urba, D L Longo, et al.
Blood|March 27, 2001
A prospective randomized phase II trial of GM-CSF priming to prevent topotecan-induced neutropenia in chemotherapy-naive patients with malignant melanoma or renal cell carcinomaJ E Janik, L L Miller, E L Korn, et al.
Clinical Immunology (Orlando, Fla.)|December 22, 1999
Treatment with tumor necrosis factor-alpha and granulocyte-macrophage colony-stimulating factor increases epidermal Langerhans' cell numbers in cancer patientsJ E Janik, L L Miller, W C Kopp, et al.
Cancer Journal (Sudbury, Mass.)|July 6, 2000
Combination chemotherapy followed by an immunotoxin (anti-B4-blocked ricin) in patients with indolent lymphoma: results of a phase II studyD L Longo, P L Duffey, J G Gribben, et al.
Pageof 3

Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
Cancer Investigation|July 29, 1998
A phase II study of carboplatin, cisplatin, interferon-alpha, and tamoxifen for patients with metastatic melanomaB L Gause, W H Sharfman, J E Janik, et al.
Blood|April 1, 1997
Adoptive transfer of anti-CD3-activated CD4+ T cells plus cyclophosphamide and liposome-encapsulated interleukin-2 cure murine MC-38 and 3LL tumors and establish tumor-specific immunityM L Saxton, D L Longo, H E Wetzel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1993
Treatment of cancer patients with ex vivo anti-CD3-activated killer cells and interleukin-2B D Curti, D L Longo, A C Ochoa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 1995
Alterations in T cell receptor and signal transduction molecules in melanoma patientsA H Zea, B D Curti, D L Longo, et al.
The New England Journal of Medicine|March 18, 1993
The effects of treatment with interleukin-1 alpha on platelet recovery after high-dose carboplatinJ W Smith, D L Longo, W G Alvord, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1992
The toxic and hematologic effects of interleukin-1 alpha administered in a phase I trial to patients with advanced malignanciesJ W Smith, W J Urba, B D Curti, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|March 1, 1996
Endocrine effects of IL-1 alpha and beta administered in a phase I trial to patients with advanced cancerB D Curti, W J Urba, D L Longo, et al.
Blood|March 27, 2001
A prospective randomized phase II trial of GM-CSF priming to prevent topotecan-induced neutropenia in chemotherapy-naive patients with malignant melanoma or renal cell carcinomaJ E Janik, L L Miller, E L Korn, et al.
Clinical Immunology (Orlando, Fla.)|December 22, 1999
Treatment with tumor necrosis factor-alpha and granulocyte-macrophage colony-stimulating factor increases epidermal Langerhans' cell numbers in cancer patientsJ E Janik, L L Miller, W C Kopp, et al.
Cancer Journal (Sudbury, Mass.)|July 6, 2000
Combination chemotherapy followed by an immunotoxin (anti-B4-blocked ricin) in patients with indolent lymphoma: results of a phase II studyD L Longo, P L Duffey, J G Gribben, et al.
Pageof 3